Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25


Metformin: A candidate for the treatment of gynecological tumors based on drug repositioning.

Irie H, Banno K, Yanokura M, Iida M, Adachi M, Nakamura K, Umene K, Nogami Y, Masuda K, Kobayashi Y, Tominaga E, Aoki D.

Oncol Lett. 2016 Feb;11(2):1287-1293. Epub 2016 Jan 7.


Understanding the Key to Targeting the IGF Axis in Cancer: A Biomarker Assessment.

Lodhia KA, Tienchaiananda P, Haluska P.

Front Oncol. 2015 Jul 8;5:142. doi: 10.3389/fonc.2015.00142. eCollection 2015 Jul 8. Review.


IGF1R- and ROR1-Specific CAR T Cells as a Potential Therapy for High Risk Sarcomas.

Huang X, Park H, Greene J, Pao J, Mulvey E, Zhou SX, Albert CM, Moy F, Sachdev D, Yee D, Rader C, Hamby CV, Loeb DM, Cairo MS, Zhou X.

PLoS One. 2015 Jul 14;10(7):e0133152. doi: 10.1371/journal.pone.0133152. eCollection 2015 Jul 14.


Can we unlock the potential of IGF-1R inhibition in cancer therapy?

King H, Aleksic T, Haluska P, Macaulay VM.

Cancer Treat Rev. 2014 Oct;40(9):1096-105. doi: 10.1016/j.ctrv.2014.07.004. Epub 2014 Aug 4. Review.


Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children's Oncology Group.

Weigel B, Malempati S, Reid JM, Voss SD, Cho SY, Chen HX, Krailo M, Villaluna D, Adamson PC, Blaney SM.

Pediatr Blood Cancer. 2014 Mar;61(3):452-6. doi: 10.1002/pbc.24605. Epub 2013 Aug 17.


Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors.

Macaulay VM, Middleton MR, Protheroe AS, Tolcher A, Dieras V, Sessa C, Bahleda R, Blay JY, LoRusso P, Mery-Mignard D, Soria JC.

Ann Oncol. 2013 Mar;24(3):784-91. doi: 10.1093/annonc/mds511. Epub 2012 Oct 26.


Molecular imaging of insulin-like growth factor 1 receptor in cancer.

Zhang Y, Cai W.

Am J Nucl Med Mol Imaging. 2012 Apr 15;2(2):248-259. Epub 2012 Mar 28.


Evaluation of a novel hexavalent humanized anti-IGF-1R antibody and its bivalent parental IgG in diverse cancer cell lines.

Chang CH, Wang Y, Trisal P, Li R, Rossi DL, Nair A, Gupta P, Losman M, Cardillo TM, Rossi EA, Goldenberg DM.

PLoS One. 2012;7(8):e44235. doi: 10.1371/journal.pone.0044235. Epub 2012 Aug 31.


The insulin receptor: a new target for cancer therapy.

Malaguarnera R, Belfiore A.

Front Endocrinol (Lausanne). 2011 Dec 6;2:93. doi: 10.3389/fendo.2011.00093. eCollection 2011 Dec 6.


Quantifying insulin receptor isoform expression in FFPE breast tumors.

Harrington SC, Weroha SJ, Reynolds C, Suman VJ, Lingle WL, Haluska P.

Growth Horm IGF Res. 2012 Jun-Aug;22(3-4):108-15. doi: 10.1016/j.ghir.2012.04.001. Epub 2012 Apr 30.


Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group.

Malempati S, Weigel B, Ingle AM, Ahern CH, Carroll JM, Roberts CT, Reid JM, Schmechel S, Voss SD, Cho SY, Chen HX, Krailo MD, Adamson PC, Blaney SM.

J Clin Oncol. 2012 Jan 20;30(3):256-62. doi: 10.1200/JCO.2011.37.4355. Epub 2011 Dec 19.


Akt/mTOR counteract the antitumor activities of cixutumumab, an anti-insulin-like growth factor I receptor monoclonal antibody.

Shin DH, Min HY, El-Naggar AK, Lippman SM, Glisson B, Lee HY.

Mol Cancer Ther. 2011 Dec;10(12):2437-48. doi: 10.1158/1535-7163.MCT-11-0235. Epub 2011 Oct 6.


A candidate targeting molecule of insulin-like growth factor-I receptor for gastrointestinal cancers.

Adachi Y, Yamamoto H, Ohashi H, Endo T, Carbone DP, Imai K, Shinomura Y.

World J Gastroenterol. 2010 Dec 14;16(46):5779-89.


Anti-insulin growth factor receptor therapy in Ewing sarcoma.

Isakoff MS, Marina N.

F1000 Med Rep. 2009 Aug 17;1. pii: 62. doi: 10.3410/M1-62.


Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases?

Smith TJ.

Pharmacol Rev. 2010 Jun;62(2):199-236. doi: 10.1124/pr.109.002469. Epub 2010 Apr 14. Review.


Prolactin enhances insulin-like growth factor I receptor phosphorylation by decreasing its association with the tyrosine phosphatase SHP-2 in MCF-7 breast cancer cells.

Carver KC, Piazza TM, Schuler LA.

J Biol Chem. 2010 Mar 12;285(11):8003-12. doi: 10.1074/jbc.M109.066480. Epub 2010 Jan 15.


Selective disruption of insulin-like growth factor-1 (IGF-1) signaling via phosphoinositide-dependent kinase-1 prevents the protective effect of IGF-1 on human cancer cell death.

Alberobello AT, D'Esposito V, Marasco D, Doti N, Ruvo M, Bianco R, Tortora G, Esposito I, Fiory F, Miele C, Beguinot F, Formisano P.

J Biol Chem. 2010 Feb 26;285(9):6563-72. doi: 10.1074/jbc.M109.097410. Epub 2009 Dec 31.


The type I insulin-like growth factor receptor regulates cancer metastasis independently of primary tumor growth by promoting invasion and survival.

Sachdev D, Zhang X, Matise I, Gaillard-Kelly M, Yee D.

Oncogene. 2010 Jan 14;29(2):251-62. doi: 10.1038/onc.2009.316. Epub 2009 Oct 19.


Fluorescent tumour imaging of type I IGF receptor in vivo: comparison of antibody-conjugated quantum dots and small-molecule fluorophore.

Zhang H, Zeng X, Li Q, Gaillard-Kelly M, Wagner CR, Yee D.

Br J Cancer. 2009 Jul 7;101(1):71-9. doi: 10.1038/sj.bjc.6605103. Epub 2009 Jun 2.


Sequencing of type I insulin-like growth factor receptor inhibition affects chemotherapy response in vitro and in vivo.

Zeng X, Sachdev D, Zhang H, Gaillard-Kelly M, Yee D.

Clin Cancer Res. 2009 Apr 15;15(8):2840-9. doi: 10.1158/1078-0432.CCR-08-1401. Epub 2009 Apr 7.

Supplemental Content

Support Center